Tarif Tip - Tiotropium Bromide 18mcg inhalation powder capsules
Tarif Tip - Tiotropium Bromide 18mcg inhalation powder capsules
Q: I have a prescription for Tiotropium bromide 18mcg inhalation powder capsules. We usually supply Spiriva® powder capsules but our PMR is suggesting a product called Tiogiva® 18mcg inhalation powder capsules. Can we supply these ones?
A: Tiogiva® 18mcg inhalation powder capsules are a recently launched product made by Glenmark Pharmaceuticals.
It has bioequivalence with Spiriva® powder capsules and delivers a dose that is equivalent to 10mcg of tiotropium.
Its licensed indication is as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD)
The capsules have their own inhalation device and are available as a complete pack with device or a refill pack of capsules alone. The capsules should only be used with the Tiogiva® inhaler device, as they are not compatible with the Spiriva Handihaler®.
Pricing
The current Drug Tariff price (June 2021) for tiotropium bromide 18mcg inhalation powder capsules is based on Spiriva®. Whilst currently pharmacists will not be out of pocket by supplying Spiriva® against a generic prescription, it would be reasonable to assume that the tariff price will be corrected to reflect the availability of generic versions.
Product |
List Price (June 2021) |
Spiriva® 18mcg inhalation powder capsules + device |
£34.87 |
Spiriva® 18mcg inhalation powder capules refill pack |
£33.50 |
Tiogiva® 18mcg inhalation powder capsules + device |
£19.99 |
Tiogiva® 18mcg inhalation powder capsules refill pack |
£19.20 |
Advice for Pharmacy teams
Pharmacists should ensure that patients:
- agree to a switch in their inhaler device
- are counselled on the correct use of the new device
- are counselled on potential taste differences
Prescribers should be advised that where they or their patients have a specific preference for one particular brand this should be specified on the prescription to ensure correct supply.
In the absence of a specific product being prescribed then either of the products could be supplied but pharmacists would need to ensure that patients are supplied with a complete pack of device and inhalation powder capsules initially.
In the interests of consistency and patient adherence to the prescribed treatment the same inhaler device should be supplied each time. A record should be made on the patient’s PMR of the correct device to supply.
There is another tiotropium bromide capsule product (Braltus®) that can be prescribed but this is listed as 10mcg inhalation powder capsules so although Tiogiva® inhalation powder capsules deliver this dose they cannot be dispensed for prescriptions for tiotropium bromide 10mcg inhalation powder capsules.